Treatment cost of non-small cell lung cancer in three European countries: Comparisons across France, Germany, and England using administrative databases

Journal of Medical Economics

Volumn 18, Issue 7, 2015, Pages 525-532

  McGuire, A ^a,b   Martin, M ^b   Lenz, C ^c   Sollano, J A ^c  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b Mapi   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

Cost; Europe; NSCLC; Retrospective

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG COST; FEMALE; FOLLOW UP; FRANCE; GERMANY; HEALTH CARE COST; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; ICD-10; ICD-9; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SMALL CELL LUNG CANCER; UNITED KINGDOM; AGE; CARCINOMA, NON-SMALL-CELL LUNG; ECONOMICS; EUROPE; FACTUAL DATABASE; HEALTH SERVICE; HOSPITAL CHARGE; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; SMOKING; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UTILIZATION; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, FACTUAL; EUROPE; FEMALE; HEALTH SERVICES; HOSPITAL CHARGES; HUMANS; INCIDENCE; LENGTH OF STAY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; SMOKING;

EID: 84942806156     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1032974     Document Type: Article

References (11)

1. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 2013;68:551-64
2. De Angelis AR, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014;15:23-34
3. Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005;50:143-54
4. Pompen M, Gok M, Novak A, et al. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. Lung Cancer 2009;64:110-16
5. Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008;14:297-306
6. Health and Social Care Information Centre. UK Lung Cancer National Audit Report, 2012. 2013. www.cancerresearchuk.org
7. Cancer Research UK 2. Let's Beat Cancer Soon. France, 2015. http://globocan.iarc.fr
8. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. UK, 2015. www.pssru.ac.uk
9. Curtis L. Unit Costs of Health and Social Care. Canterbury, UK: PSSRU, 2012
10. NICE. Costing template for Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer, NICE Guidance, TA192. UK, 2010. www.nice.org.uk
11. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403